PH12022553084A1 - Novel inhalant - Google Patents
Novel inhalantInfo
- Publication number
- PH12022553084A1 PH12022553084A1 PH1/2022/553084A PH12022553084A PH12022553084A1 PH 12022553084 A1 PH12022553084 A1 PH 12022553084A1 PH 12022553084 A PH12022553084 A PH 12022553084A PH 12022553084 A1 PH12022553084 A1 PH 12022553084A1
- Authority
- PH
- Philippines
- Prior art keywords
- inhalant
- novel
- cepharanthine
- covid
- therapeutic agent
- Prior art date
Links
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- VQAWRQZAAIQXHM-UHFFFAOYSA-N Cepharanthine Natural products O1C(C=C2)=CC=C2CC(C=23)N(C)CCC3=CC=3OCOC=3C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C(O)C1=C2 VQAWRQZAAIQXHM-UHFFFAOYSA-N 0.000 abstract 1
- YVPXVXANRNDGTA-WDYNHAJCSA-N cepharanthine Chemical compound C1C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@H](C2=C3)N(C)CCC2=CC(OC)=C3OC2=C(OCO3)C3=CC3=C2[C@H]1N(C)CC3 YVPXVXANRNDGTA-WDYNHAJCSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020085471 | 2020-05-14 | ||
| PCT/JP2021/018328 WO2021230340A1 (ja) | 2020-05-14 | 2021-05-14 | 新規吸入剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022553084A1 true PH12022553084A1 (en) | 2024-03-25 |
Family
ID=78524492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/553084A PH12022553084A1 (en) | 2020-05-14 | 2021-05-14 | Novel inhalant |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230338365A1 (https=) |
| EP (1) | EP4151211A1 (https=) |
| JP (1) | JPWO2021230340A1 (https=) |
| KR (1) | KR20230011282A (https=) |
| CN (1) | CN117083063A (https=) |
| AU (1) | AU2021270426A1 (https=) |
| PH (1) | PH12022553084A1 (https=) |
| WO (1) | WO2021230340A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| JP2024178477A (ja) * | 2021-11-04 | 2024-12-25 | 興和株式会社 | カプセル剤 |
| JP2024178478A (ja) * | 2021-11-04 | 2024-12-25 | 興和株式会社 | 医薬品 |
| CN118555958A (zh) * | 2021-11-17 | 2024-08-27 | 国立感染症研究所所长代表的日本国 | 含有来自金线吊乌龟的生物碱的制剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1201737C (zh) * | 2003-06-19 | 2005-05-18 | 广州暨南生物医药研究开发基地有限公司 | 千金藤素在制备抗sars病毒药物中的应用 |
| WO2007011396A2 (en) * | 2004-10-29 | 2007-01-25 | President And Fellows Of Harvard College | Particles for treatment of pulmonary infection |
| CN1771953A (zh) * | 2005-11-01 | 2006-05-17 | 袁继民 | 一种含有千金藤素的药物 |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| CN110151691A (zh) * | 2019-06-19 | 2019-08-23 | 宁夏医科大学 | 一种千金藤素纳米混悬液及其制备方法 |
-
2021
- 2021-05-14 PH PH1/2022/553084A patent/PH12022553084A1/en unknown
- 2021-05-14 JP JP2022522211A patent/JPWO2021230340A1/ja active Pending
- 2021-05-14 AU AU2021270426A patent/AU2021270426A1/en not_active Abandoned
- 2021-05-14 US US17/998,308 patent/US20230338365A1/en not_active Abandoned
- 2021-05-14 WO PCT/JP2021/018328 patent/WO2021230340A1/ja not_active Ceased
- 2021-05-14 EP EP21804702.5A patent/EP4151211A1/en not_active Withdrawn
- 2021-05-14 KR KR1020227038651A patent/KR20230011282A/ko not_active Withdrawn
- 2021-05-14 CN CN202180035149.1A patent/CN117083063A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021230340A1 (ja) | 2021-11-18 |
| CN117083063A (zh) | 2023-11-17 |
| JPWO2021230340A1 (https=) | 2021-11-18 |
| AU2021270426A1 (en) | 2022-12-08 |
| US20230338365A1 (en) | 2023-10-26 |
| EP4151211A1 (en) | 2023-03-22 |
| KR20230011282A (ko) | 2023-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022553084A1 (en) | Novel inhalant | |
| EP4279535A3 (en) | Method for preparing polyols | |
| MY199348A (en) | Process for preparing optically active 2,3-dihydrothiazolo[3,2-a]pyrimidin-4-ium compounds | |
| PH12020550585A1 (en) | Sting modulator compounds, and methods of making and using | |
| ZA202308002B (en) | Pyrimidopyran compound | |
| PH12014500308A1 (en) | Cyclopropaneamine compound | |
| PH12021553010A1 (en) | Cot modulators and methods of use thereof | |
| PH12019502093A1 (en) | Novel ester compounds, method for the production thereof and use thereof | |
| MX2025010357A (es) | Degradador de irak4, y uso del mismo | |
| PH12014502752A1 (en) | Novel cyclic depsipeptide derivative and pest control agent compromising same | |
| GEP20125512B (en) | Process for synthesis of agomelatin | |
| EP4410773A3 (en) | Process for the synthesis of (s) 3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid | |
| ZA202101487B (en) | Novel compounds | |
| PH12022550392A1 (en) | Compositions and methods of treating vascular diseases | |
| MY210361A (en) | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| MX2021008654A (es) | Complejo de gadolinio y un ligando quelatante derivado de pcta diastereoisomericamente enriquecido y metodo de sintesis. | |
| MX2023011976A (es) | Sintesis de compuestos analogos de rapamicina. | |
| AU2020394241A8 (en) | Composition for inhibiting HMF production comprising allulose disaccharide | |
| WO2023028168A3 (en) | Methods of using antibody-drug-conjugates | |
| MX2021006692A (es) | Proceso mejorado para preparar ozanimod. | |
| MX2023011004A (es) | Compuestos para regular la inmunidad entrenada y métodos para usarlos. | |
| MX2023004955A (es) | Compuestos de aminotiazol deuterados como compuestos antiviricos. | |
| PH12020500572A1 (en) | Substituted alkynylene compounds as anticancer agents | |
| IL279168B (en) | A process for the preparation of eribulin |